New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an ...

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that ...

Novo Nordisk's U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its ...

Novo Nordisk is making the case for its diabetes pill, which it hopes will allow it to fight off competition from rivals in a highly competitive market. The company announced the completion of two ...

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

“This result further weakens the outlook for CagriSema and raises doubts about Novo’s future drug candidates,” Evans said in a note. The shares fell as much as 8.8% in Copenhagen, the ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

the active ingredient in Novo’s weight-loss drugs. It comes after the FDA said the drug’s shortage is over, effectively closing the pathway for compounding pharmacies to offer alternative ...